Futura Medical PLC - Surrey-based sexual health products company - Announces that the next milestone payment of $5.0 million, due under its agreement with Haleon PLC, has been triggered by Haleon’s distribution of online pre-orders and the availability of Eroxon in US retailers. Eroxon is a fast-acting gel used to treat erectile dysfunction, which has been available without a prescription in UK pharmacies since March last year. Futura Medical struck a licensing deal with Haleon for the gel in July 2023, which has led to its availability in the US from October this year. Futura Medical expects to receive the payment from Haleon shortly.

Current stock price: 33.20 pence, up 2.0% in London on Monday morning

12-month change: down 20%

Copyright 2024 Alliance News Ltd. All Rights Reserved.